Group 1: Verint Systems Inc. - Verint Systems Inc. is under investigation related to its sale to Thoma Bravo, with shareholders set to receive $20.50 per share in cash [1] Group 2: Electronic Arts Inc. - Electronic Arts Inc. is involved in a sale to an investor consortium including PIF, Silver Lake, and Affinity Partners, with stockholders expected to receive $210.00 in cash per share [2] Group 3: Merus N.V. - Merus N.V. is being sold to GEnmad A/S, with stockholders to receive $97.00 in cash per share [3] Group 4: The Farmers Savings Bank - The Farmers Savings Bank is set to be sold to Civista Bancshares, Inc., where each common share will convert into $69,850 in cash and approximately 2,869 Civista common shares [4]

Core Insights - Merus N.V. (NASDAQ:MRUS) is highlighted as one of the best biotech stocks to buy, with Barclays initiating coverage and setting a price target of $112 and an Overweight rating [1] - The approval of zenocutuzumab for rare malignancies has validated Merus's platform commercially [1] Group 1: Clinical Developments - Merus's Phase 3 clinical asset, petosemtamab, is undergoing two potentially registration-enabling Phase 3 trials for frontline and previously treated metastatic head and neck cancers [2] - The clinical derisking of petosemtamab in head and neck malignancies, along with potential value creation in colorectal cancer through year-end 2026, presents a significant opportunity for share gain [2] Group 2: Company Overview - Merus N.V. is a biotechnology company focused on developing antibody-based cancer treatments, with key initiatives including Zenocutuzumab and Petosemtamab (MCLA-158) [3]

Group 1 - Halper Sadeh LLC is investigating Electronic Arts Inc. for potential violations related to its sale to an investor consortium for $210.00 per share in cash [1] - Merus N.V. is under investigation for its sale to Genmab A/S for $97.00 per share, with the firm seeking increased consideration for shareholders [2] - The firm offers free consultations for shareholders to discuss their legal rights and options regarding these transactions [3] Group 2 - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [3]

Accessibility StatementSkip Navigation NEW YORK, Sept. 30, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Merus N.V. (NASDAQ: MRUS) related to its sale to GEnmad A/S. Under the terms of the propose ...

We recently published 10 Stocks With 10-60% Upside. Merus NV (NASDAQ:MRUS) is one of the top performers on Monday. Shares of Merus NV soared to a new record high on Monday, as investors gobbled up shares following news that it was set to be acquired by Genmab AS at a 41-percent premium. In a statement, Genmab AS said that it entered into an agreement with Merus NV (NASDAQ:MRUS) for the acquisition of the latter, through its subsidiary, Purchaser, for $8 billion. Merus (MRUS) Soars to New High on Genmab ...

Core Insights - Genmab has agreed to acquire all shares of Merus for $97 per share, totaling $8 billion, enhancing its oncology pipeline [1][4] - The acquisition is supported by both companies' boards and is expected to transition Genmab to a fully owned business model [1][2] - The deal is projected to close in early Q1 2026, with a key asset being Merus' petosemtamab, currently in Phase III development [2][3] Financial Details - The acquisition price represents a 41% premium over Merus' closing stock price on September 26, 2025, and a 44% premium over the 30-day volume-weighted average price of $67.42 [4] - Genmab plans to finance the acquisition through existing cash and $5.5 billion in non-convertible debt, with backing from Morgan Stanley Senior Funding [4] Strategic Implications - The acquisition aligns with Genmab's long-term strategy to become a global biotechnology leader, providing sustainable growth into the next decade [6] - Petosemtamab is expected to be a transformative therapy for head and neck cancer, with potential launch in 2027 depending on clinical outcomes and regulatory approvals [3][6] Advisory Information - Genmab is advised by PJT Partners and Morgan Stanley & Co International, with legal counsel from A&O Shearman and Kromann Reumert [5] - Merus is advised by Jefferies, with legal counsel from Latham & Watkins and NautaDutilh [5]

Core Viewpoint - Genmab A/S has announced a cash acquisition of Merus NV for $97.00 per share, valuing the transaction at approximately $8 billion, which has been approved by both companies' boards [1][3]. Group 1: Acquisition Details - The acquisition price of $97.00 per share represents a premium of about 41% over Merus's closing price of $68.89 on September 26, 2025, and a 44% premium over the 30-day volume-weighted average price of $67.42 [3]. - The acquisition is expected to accelerate Genmab's transition to a fully integrated model, expanding its revenue sources and driving sustained growth over the next decade [3]. Group 2: Strategic Fit and Product Pipeline - Merus is a clinical-stage biotechnology company with a late-stage breakthrough therapy, Petosemtamab, currently in Phase III clinical development [3]. - The acquisition will integrate Petosemtamab into Genmab's late-stage pipeline, aligning strategically with Genmab's expertise in developing and commercializing antibody therapies for oncology [3][6]. - Following the transaction, Genmab will have four proprietary projects expected to lead to multiple new drug launches by 2027 [3]. Group 3: Clinical Development and Market Potential - Petosemtamab is an EGFRxLGR5 bispecific antibody that has the potential to become a first-line and best-in-class treatment for head and neck cancer, having received two Breakthrough Therapy Designations (BTD) from the FDA [3][4]. - Merus is conducting two Phase III clinical trials for head and neck cancer, with top-line interim data expected in 2026 [4]. - Genmab anticipates that Petosemtamab could be launched by 2027, pending clinical results and regulatory approvals, with projected sales reaching at least $1 billion by 2029 [6].

Group 1: Hong Kong Stocks - China Metallurgical Group (01618) rose nearly 7%, with institutions stating that the value of this resource-rich construction company needs urgent reassessment [1] - Rongchang Bio (09995) increased over 5%, as its innovative ophthalmic drug RC28 has been submitted for listing, following a partnership with Santen China [1] - Laikang Pharmaceutical-B (02105) surged nearly 6%, with a cumulative increase of 36% over the last three trading days, driven by positive preliminary results from the Phase I clinical MAD study of LAE102 [1] - UBTECH Robotics (09880) rose over 5%, with a report from CMB International recommending UBTECH as the top pick in the humanoid robot sector and raising its target price [1] - Innovent Biologics (09969) increased over 6%, as the company announced the first prescriptions for Tanshitumomab in several provinces [1] - BrainCo-B (06681) surged over 16%, benefiting from policy catalysts in the brain-computer interface industry, with its cognitive impairment digital therapy product having a first-mover advantage [1] - Yaoshi Bang (09885) rose over 10%, with high-margin business accelerating growth and POCT devices expected to see increased deployment in the second half of the year [1] - DCH Holdings (00179) fell over 7%, as Citigroup downgraded its investment rating from "Buy" to "Neutral," citing limited upside potential for the stock [1] - Minmetals Resources (01208) rose over 2%, planning to issue $500 million zero-coupon convertible bonds maturing in 2030 for overseas debt refinancing [1][2] Group 2: US Stocks - Alibaba (BABA.US) rose 4.65%, with Morgan Stanley reiterating an "Overweight" rating and raising the ADR target price from $165 to $200 [3] - Li Auto (LI.US) increased 3.57%, as the Li One officially commenced delivery at the Changzhou smart manufacturing base, with a report indicating that the i6 model's sales performance is expected to outperform the i8 [3] - JD.com (JD.US) rose 0.15%, announcing that the 2025 Double 11 shopping festival will start on October 9 at 8 PM, two days earlier than last year [3] - Xpeng Motors (XPEV.US) increased 1.76%, with the company announcing that the Xpeng MONA M03 has delivered a total of 180,000 units [3] - New Oriental (EDU.US) rose 4.38%, with a report indicating that the overall business development of the group is stabilizing [3] - Merus (MRUS.US) surged 35.97%, following an agreement with Danish biotech company Genmab for a cash acquisition at $97 per share [3] - Novo Nordisk (NVO.US) fell 0.20%, as Morgan Stanley downgraded its rating to "Sell" and reduced the target price from $99 to $47 [4] - MoonLake (MLTX.US) plummeted 89.93%, with trial results for its therapeutic drug falling far below expectations, leading to a significant target price cut by RBC [4] - TSMC (TSM.US) fell 0.05%, reaffirming that it has not engaged in discussions regarding potential investments or collaborations with any companies [4] - Micron Technology (MU.US) rose 4.22%, with Morgan Stanley predicting that the storage industry price increase cycle may continue into next year [4]

Core Insights - Genmab A/S is acquiring Merus N.V. for $97 per share in an all-cash transaction valued at approximately $8 billion, aimed at enhancing its oncology portfolio [1][6] - The acquisition includes Merus' late-stage asset, petosemtamab, which is in Phase 3 development, expected to accelerate Genmab's transition to a wholly owned model [3][6] - Following the acquisition, Genmab will have four proprietary programs ready to drive multiple new drug launches, diversifying its revenue streams [4] Financial Metrics - Leerink Partners has set a price target of $34 for GMAB, indicating a potential increase of about 16.61% from its current trading price of $29.33 [2][6] - Genmab's market capitalization is approximately $18.51 billion, with a trading volume of 5.03 million shares on NASDAQ [4] - Merus' stock surged by 38% following the acquisition announcement, reflecting a positive market response [5] Strategic Implications - The acquisition is a significant step for Genmab in expanding its capabilities in cancer treatment and is expected to support sustained growth into the next decade [3][5] - The deal is anticipated to close by early in the first quarter of 2026, aligning with Genmab's strategic goals [3]

Company Overview - Merus N.V. is a biotechnology company specializing in innovative cancer therapies, particularly known for its bispecific antibody technology aimed at effectively targeting and destroying cancer cells [1] - The company competes with other biotech firms, notably Genmab A/S, which is currently involved in a significant transaction with Merus [1] Stock Performance and Price Target - On September 29, 2025, Wells Fargo set a price target of $97 for MRUS, indicating a potential increase of approximately 2.69% from its trading price of $94.46 at that time [2] - The agreed sale price of $97 per share in the ongoing acquisition by Genmab A/S aligns with this price target [2] Shareholder Investigation - Halper Sadeh LLC is investigating the fairness of the $97 sale price for Merus shareholders, assessing whether the company and its board have fulfilled their duties in this transaction [3] - The current stock price of MRUS is $94.12, reflecting a significant increase of 36.62% over the past year [3] Market Capitalization and Trading Activity - Merus has experienced a notable rise in stock price, with a fluctuation range between $94.06 and $94.55, marking the highest price over the past year, while the lowest was $33.19 [4] - The company's market capitalization is approximately $7.12 billion, indicating a substantial presence in the biotech sector [4] - Today's trading volume for MRUS is 14.86 million shares, suggesting strong investor interest [5]